Vizsgálati helyszín
Ascension Saint Francis Hospital-Milwaukee
Milwaukee, Wisconsin 53215, Egyesült ÁllamokMég nincs intézményhez kötve
Az itteni vizsgálatok
Miről szól a helyszín 14 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 2. fázis4 vizsgálat
- 3. fázis4 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz9 vizsgálat
- Toboroz5 vizsgálat
- Fő szponzor
- National Cancer Institute (NCI)8 vizsgálat
- Alliance for Clinical Trials in Oncology3 vizsgálat
- ECOG-ACRIN Cancer Research Group2 vizsgálat
- NRG Oncology1 vizsgálat
Futó vizsgálatok
Toboroz
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
NCT07283939· Alliance for Clinical Trials in Oncology· Forrás
Contact: Kamal Kant Singh Abbi (principal investigator)
Toboroz
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
NCT06295367· ECOG-ACRIN Cancer Research Group· Forrás
Contact: Jonathan S. Treisman (principal investigator)
Toboroz
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
NCT05673148· 2. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Kamal Kant Singh Abbi (principal investigator)
Toboroz
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
NCT05080673· NRG Oncology· Forrás
Contact: Director, Department of Regulatory Affairs
Toboroz
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
NCT04566328· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Contact: Jonathan S. Treisman (principal investigator)
Fut, nem toboroz
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
NCT04310020· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
NCT04214067· 3. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
NCT04242095· Alliance for Clinical Trials in Oncology· Forrás
Contact: Jonathan S. Treisman (principal investigator)
Fut, nem toboroz
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
NCT03952585· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
NCT03907488· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
NCT03698019· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
NCT03737981· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02465060· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738· National Cancer Institute (NCI)· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek